Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.

Address: School of Psychology, University of New South Wales, Sydney, Australia; Neuroscience Research Australia, Sydney, Australia. Electronic address: [email protected].; Clinical Insights, Inc., Maryland, MD.; Department of Psychiatry Instituto de Investigación Sanitaria (imas12), Hospital Universitario 12 de Octubre, & Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM. Madrid, Spain.; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN; Regenstrief Institute, Inc., Indiana University Center for Aging Research, Indianapolis, IN.; Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, UNSW Sydney, Australia.; Department of Psychiatry, Robert Wood Johnson Medical School, New Brunswick, NJ.; Alzheimer's Disease and Memory Disorder's Program, Department of Neurology, Barrow Neurological Institute, Phoenix, AZ.; Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute, and O'Brien Institute of Public Health, University of Calgary, Calgary, Canada.; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, University of Toronto, Toronto, Canada.; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.; Geriatric Research Education and Clinical Center, Central Arkansas Veterans Healthcare System, Little Rock, AR.; Division of Geriatric Psychiatry, First Department of Psychiatry, National and Kapodistrian University of Athens, Athens, Greece.; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD.; Institute for Memory Impairments and Neurological Disorders (UCI MIND), and Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine CA.